Viatris to Acquire Pacira BioSciences for $1.65 Billion, Expanding Non-Opioid Pain Portfolio

{
  "signal_id": "f2da7bbc-9bfc-20c4-2f70-b9ba329148fa",
  "signal_type": "news",
  "signal_subtype": "acquires",
  "detected_at": "2026-10-08T12:37:54+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "url": "https://www.citybiz.co/article/915963/viatris-to-acquire-pacira-biosciences-for-1-65-billion-expanding-non-opioid-pain-portfolio/",
    "title": "Viatris to Acquire Pacira BioSciences for $1.65 Billion, Expanding Non-Opioid Pain Portfolio - citybiz",
    "excerpt": "Viatris Inc . (Nasdaq: VTRS) has agreed to acquire Pacira BioSciences Inc . (Nasdaq: PCRX) for approximately $1.65 billion in cash, expanding its innovative medicines portfolio and establishing a stronger position in the market for non-opioid pain management therapies. Under the definitive agreement, Viatris will acquire all outstanding Pacira shares for $36.50 per share in cash. The transaction has been unanimously approved by both companies’ boards of directors and is expected to close by the end of 2026, subject to regulatory approvals and other customary conditions. The acquisition will add two established, patent-protected medicines to Viatris’ portfolio: EXPAREL, a long-acting local anesthetic used for postsurgical pain management, and ZILRETTA, an extended-release injectable treatment for osteoarthritis knee pain. Pacira generated approximately $746 million in revenue and $177 million in adjusted EBITDA during the 12 months ended June 30, 2026. Viatris expects the transaction to be immediately accretive to its financial guidance metrics. “The pending acquisition of Pacira BioSciences is an important step in advancing our strategy to build our innovative medicines business,” said Scott A. Smith , CEO of Viatris. Smith said EXPAREL and ZILRETTA complement the company’s fast-acting meloxicam opportunity and strengthen its position in non-opioid pain management, where...",
    "summary": "Viatris has agreed to acquire Pacira BioSciences for approximately $1.65 billion in cash.",
    "planning": true,
    "image_url": "https://www.citybiz.co/wp-content/uploads/2026/10/Pacira-BioSciences.jpg",
    "confidence": 0.95,
    "published_at": "2026-10-08T12:37:54Z",
    "article_sentence": "Viatris Inc . (Nasdaq: VTRS) has agreed to acquire Pacira BioSciences Inc . (Nasdaq: PCRX) for approximately $1.65 billion in cash, expanding its innovative medicines portfolio and establishing a stronger position in the market for non-opioid pain management therapies.",
    "amount_normalized": 1650000000,
    "related_company_name": "Pacira BioSciences Inc.",
    "related_company_domain": "pacira.com"
  }
}

curl https://signals.autobound.ai/v1/signals/f2da7bbc-9bfc-20c4-2f70-b9ba329148fa \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"viatris.com","limit":20}'